Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Perrigo Company PLC, (NYSE:PRGO) was hit with a downgrade from Deutsche Bank after an eventful week that included the announced separation of its prescription pharmaceutical business and its second-quarter report.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Deutsche Bank analyst Gregg Gilbert downgraded Perrigo from Buy to Hold and lowered the price target from $93 to $78.
The Thesis
In light of soft Q2 results and a lowered outlook, Deutsche Bank is moving to the sidelines for Perrigo's generics and consumer businesses, Gilbert said in the downgrade note. (See the analyst's track record here.)
“The company’s strategic decision to separate the Rx business from the consumer business could be a good long-term decision, but it will at a minimum take some time for the market to fully assess and understand the financial and operational merits of this move and whether and how it can affect shareholder value," the analyst said.
It's important for Perrigo to reestablish "meet-or-beat" quarterly performance, Gilbert said.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
In Q2, Perrigo reported an adjusted EPS of $1.22, a 4-percent decrease in revenue and a lowered prescription sales outlook.
The Deutsche Bank analyst outlined other key takeaways from the print:
- Perrigo recognizes the advantage of separating the companies.
- The pharma company is disappointed by the performance of its animal health business, but has not made any decisions on its future.
- The launch of gProair and scopolamine are confirmed.
- “The weakness in generics was based in part on pricing dynamics that were somewhat more negative than the company had expected,” Gilbert said.
Price Action
Perrigo shares were trading down 2.76 percent to $68.10 at the time of publication Friday.
Related Links:
Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings
Analyst: Despite Industry Woes, Investigations, And Management Shake-Up, Perrigo Is A Buy
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.